Literature for peptidase S01.212: plasma kallikrein

Summary Gene structure Alignment Tree Sequences Sequence features Distribution Structure Literature Substrates Pharma

(Topics flags: A Assay, S Structure, T Target, P Specificity, K Knockout, E Expression, V Review, M Mutation, I Inhibitor. To select only the references relevant to a single topic, click the link above. See explanation.)

2025

Lee,D.K., Ghannam,A., Murugesan,N., Vincent,D., Dona,M., Cohn,D.M., Adatia,A., Smith,M.D., Audhya,P.K., Hampton,S.L. and Feener,E.P. A sensitive and specific assay to characterize plasma kallikrein activity in plasma from patients with hereditary angioedema World Allergy Organ J (2025) 18, 101135-101135. PubMed Europe PubMed DOI PMC EPMC
Liu,H., Deng,Y., Liu,J., Wang,Z., Hu,X.Q., Duan,Y., Chen,Y. and Xie,Z. Plasma Kallikrein Inhibitors for Multiple Disorders: Current Advances and Perspectives J Med Chem (2025) PubMed Europe PubMed DOI
Lopez-Lera,A., Corvillo,F., Gonzalez-Sanchez,L., Melgosa,M. and Sanchez-Corral,P. Relevance of the interactions between the complement and contact coagulation systems on renal pathology Nefrologia (Engl Ed) (2025) , 501347-501347. PubMed Europe PubMed DOI

2024

Kearney,K.J., Spronk,H.M.H., Emsley,J., Key,N.S. and Philippou,H. Plasma Kallikrein as a Forgotten Clotting Factor Semin Thromb Hemost (2024) 50, 953-961. PubMed Europe PubMed DOI V
Longhurst,H.J., Lindsay,K., Petersen,R.S., Fijen,L.M., Gurugama,P., Maag,D., Butler,J.S., Shah,M.Y., Golden,A., Xu,Y., Boiselle,C., Vogel,J.D., Abdelhady,A.M., Maitland,M.L., McKee,M.D., Seitzer,J., Han,B.W., Soukamneuth,S., Leonard,J., Sepp-Lorenzino,L., Clark,E.D., Lebwohl,D. and Cohn,D.M. CRISPR-Cas9 In Vivo Gene Editing of KLKB1 for Hereditary Angioedema N Engl J Med (2024) 390, 432-441. PubMed Europe PubMed DOI
Riedl,M.A., Bordone,L., Revenko,A., Newman,K.B. and Cohn,D.M. Clinical Progress in Hepatic Targeting for Novel Prophylactic Therapies in Hereditary Angioedema J Allergy Clin Immunol Pract (2024) 12, 911-918. PubMed Europe PubMed DOI K

2023

Bedian,V., Biris,N., Omer,C., Chung,J.K., Fuller,J., Dagher,R., Chandran,S., Harwin,P., Kiselak,T., Violin,J., Nichols,A. and Bista,P. STAR-0215 is a Novel, Long-Acting Monoclonal Antibody Inhibitor of Plasma Kallikrein for the Potential Treatment of Hereditary Angioedema J Pharmacol Exp Ther (2023) 387, 214-225. PubMed Europe PubMed DOI
Li,C., Barroeta,A.B., Wong,S.S., Kim,H.J., Pathak,M., Dreveny,I., Meijers,J.C.M. and Emsley,J. Structures of factor XI and prekallikrein bound to domain 6 of high-molecular weight kininogen reveal alternate domain 6 conformations and exosites J Thromb Haemost (2023) 21, 2378-2389. PubMed Europe PubMed DOI
Motta,G., Juliano,L. and Chagas,J.R. Human plasma kallikrein: roles in coagulation, fibrinolysis, inflammation pathways, and beyond Front Physiol (2023) 14, 1188816-1188816. PubMed Europe PubMed DOI PMC EPMC V

2022

Alfaro,E., Diaz-Garcia,E., Garcia-Tovar,S., Zamarron,E., Mangas,A., Galera,R., Nanwani-Nanwani,K., Perez-de-Diego,R., Lopez-Collazo,E., Garcia-Rio,F. and Cubillos-Zapata,C. Impaired Kallikrein-Kinin System in COVID-19 Patients' Severity Front Immunol (2022) 13, 909342-909342. PubMed Europe PubMed DOI PMC EPMC
Davie,R.L., Edwards,H.J., Evans,D.M., Hodgson,S.T., Stocks,M.J., Smith,A.J., Rushbrooke,L.J., Pethen,S.J., Roe,M.B., Clark,D.E., McEwan,P.A. and Hampton,S.L. Sebetralstat (KVD900): A Potent and Selective Small Molecule Plasma Kallikrein Inhibitor Featuring a Novel P1 Group as a Potential Oral On-Demand Treatment for Hereditary Angioedema J Med Chem (2022) 65, 13629-13644. PubMed Europe PubMed DOI I
Sohaei,D., Hollenberg,M., Janket,S.J., Diamandis,E.P., Poda,G. and Prassas,I. The therapeutic relevance of the Kallikrein-Kinin axis in SARS-cov-2-induced vascular pathology Crit Rev Clin Lab Sci (2022) , 1-16. PubMed Europe PubMed DOI V
Wang,J.K., Li,Y., Zhao,X.L., Liu,Y.B., Tan,J., Xing,Y.Y., Adi,D., Wang,Y.T., Fu,Z.Y., Ma,Y.T., Liu,S.M., Liu,Y., Wang,Y., Shi,X.J., Lu,X.Y., Song,B.L. and Luo,J. Ablation of Plasma Prekallikrein Decreases Low-Density Lipoprotein Cholesterol by Stabilizing Low-Density Lipoprotein Receptor and Protects Against Atherosclerosis Circulation (2022) 145, 675-687. PubMed Europe PubMed DOI

2021

Giangreco,N.P., Lebreton,G., Restaino,S., Jane Farr,M., Zorn,E., Colombo,P.C., Patel,J., LeVine,R., Truby,L., Soni,R.K., Leprince,P., Kobashigawa,J., Tatonetti,N.P. and Fine,B.M. Plasma kallikrein predicts primary graft dysfunction after heart transplant J Heart Lung Transplant (2021) PubMed Europe PubMed DOI
Kearney,K.J., Butler,J., Posada,O.M., Wilson,C., Heal,S., Ali,M., Hardy,L., Ahnstrom,J., Gailani,D., Foster,R., Hethershaw,E., Longstaff,C. and Philippou,H. Kallikrein directly interacts with and activates Factor IX, resulting in thrombin generation and fibrin formation independent of Factor XI Proc Natl Acad Sci U S A (2021) 118 PubMed Europe PubMed DOI
Pihl,R., Jensen,R.K., Poulsen,E.C., Jensen,L., Hansen,A.G., Thogersen,I.B., Dobo,J., Gal,P., Andersen,G.R., Enghild,J.J. and Thiel,S. ITIH4 acts as a protease inhibitor by a novel inhibitory mechanism Sci Adv (2021) 7 PubMed Europe PubMed DOI PMC EPMC
Wan,J., Vadaq,N., Konings,J., Jaeger,M., Kumar,V., de Laat,B., Joosten,L., Netea,M.G., van der Ven,A.J., DE Groot,P.G., de Mast,Q. and Roest,M. Kallikrein augments the anticoagulant function of the protein C system in thrombin generation J Thromb Haemost (2021) PubMed Europe PubMed DOI

2020

Chatterjee,P., Gheblawi,M., Wang,K., Vu,J., Kondaiah,P. and Oudit,G.Y. Interaction between the apelinergic system and ACE2 in the cardiovascular system: therapeutic implications Clin Sci (Lond) (2020) 134, 2319-2336. PubMed Europe PubMed DOI V
Fang,C. and Schmaier,A.H. Novel anti-thrombotic mechanisms mediated by Mas receptor as result of balanced activities between the kallikrein/kinin and the renin-angiotensin systems Pharmacol Res (2020) 160, 105096-105096. PubMed Europe PubMed DOI PMC EPMC V
Ivanov,I., Verhamme,I.M., Sun,M.F., Mohammed,B., Cheng,Q., Matafonov,A., Dickeson,S.K., Joseph,K., Kaplan,A.P. and Gailani,D. Protease activity in single-chain prekallikrein Blood (2020) 135, 558-567. PubMed Europe PubMed DOI
Meini,S., Zanichelli,A., Sbrojavacca,R., Iuri,F., Roberts,A.T., Suffritti,C. and Tascini,C. Understanding the Pathophysiology of COVID-19: Could the Contact System Be the Key? Front Immunol (2020) 11, 2014-2014. PubMed Europe PubMed DOI PMC EPMC
Ponczek,M.B., Shamanaev,A., LaPlace,A., Dickeson,S.K., Srivastava,P., Sun,M.F., Gruber,A., Kastrup,C., Emsley,J. and Gailani,D. The evolution of factor XI and the kallikrein-kinin system Blood Adv (2020) 4, 6135-6147. PubMed Europe PubMed DOI PMC EPMC
Xie,Z., Li,Z., Shao,Y. and Liao,C. Discovery and development of plasma kallikrein inhibitors for multiple diseases Eur J Med Chem (2020) 190, 112137-112137. PubMed Europe PubMed DOI I

2019

Fischer,C., Lamer,T., Wang,W., McKinnie,S.M.K., Iturrioz,X., Llorens-Cortes,C., Oudit,G.Y. and Vederas,J.C. Plasma kallikrein cleaves and inactivates apelin-17: palmitoyl- and PEG-extended apelin-17 analogs as metabolically stable blood pressure-lowering agents Eur J Med Chem (2019) 166, 119-124. PubMed Europe PubMed DOI
Hwang,G., Johri,A., Ng,S. and Craig,T. A review of kallikrein inhibitor lanadelumab in hereditary angioedema Immunotherapy (2019) 11, 937-944. PubMed Europe PubMed DOI
Hwang,J.R., Hwang,G., Johri,A. and Craig,T. Oral plasma kallikrein inhibitor BCX7353 for treatment of hereditary angioedema Immunotherapy (2019) 11, 1439-1444. PubMed Europe PubMed DOI I
Li,C., Voos,K.M., Pathak,M., Hall,G., McCrae,K.R., Dreveny,I., Li,R. and Emsley,J. Plasma Kallikrein Structure Reveals Apple Domain Disc Rotated Conformation Compared to Factor XI J Thromb Haemost (2019) 17, 759-770. PubMed Europe PubMed DOI S
Partridge,J.R., Choy,R.M., Silva-Garcia,A., Yu,C., Li,Z., Sham,H. and Metcalf,B. Structures of full-length plasma kallikrein bound to highly specific inhibitors describe a new mode of targeted inhibition J Struct Biol (2019) 206, 170-182. PubMed Europe PubMed DOI S I
Salu,B.R., Pando,S.C., Brito,M.V., Medina,A.F., Odei-Addo,F., Frost,C., Naude,R., Sampaio,M.U., Emsley,J., Maffei,F.H.A. and Oliva,M.L.V. Improving the understanding of plasma kallikrein contribution to arterial thrombus formation using two plant protease inhibitors Platelets (2019) 30, 305-313. PubMed Europe PubMed DOI
Sun,J.K., Maturi,R.K., Boyer,D.S., Wells,J.A., Gonzalez,V.H., Tansley,R., Hernandez,H., Maetzel,A., Feener,E.P. and Aiello,L.P. One-time intravitreal injection of KVD001, a plasma kallikrein inhibitor, in patients with central-involved diabetic macular edema and reduced vision: an open-label phase 1B study Ophthalmol Retina (2019) 3, 1107-1109. PubMed Europe PubMed DOI I
Wedi,B. Lanadelumab to treat hereditary angioedema Drugs Today (Barc) (2019) 55, 439-448. PubMed Europe PubMed DOI

2018

Aygoren-Pursun,E., Bygum,A., Grivcheva-Panovska,V., Magerl,M., Graff,J., Steiner,U.C., Fain,O., Huissoon,A., Kinaciyan,T., Farkas,H., Lleonart,R., Longhurst,H.J., Rae,W., Triggiani,M., Aberer,W., Cancian,M., Zanichelli,A., Smith,W.B., Baeza,M.L., Du-Thanh,A., Gompels,M., Gonzalez-Quevedo,T., Greve,J., Guilarte,M., Katelaris,C., Dobo,S., Cornpropst,M., Clemons,D., Fang,L., Collis,P., Sheridan,W., Maurer,M. and Cicardi,M. Oral plasma kallikrein inhibitor for prophylaxis in hereditary angioedema N Engl J Med (2018) 379, 352-362. PubMed Europe PubMed DOI I
Irmscher,S., Doring,N., Halder,L.D., Jo,E.A.H., Kopka,I., Dunker,C., Jacobsen,I.D., Luo,S., Slevogt,H., Lorkowski,S., Beyersdorf,N., Zipfel,P.F. and Skerka,C. Kallikrein cleaves C3 and activates complement J Innate Immun (2018) 10, 94-105. PubMed Europe PubMed DOI
Riedl,M.A., Aygoren-Pursun,E., Baker,J., Farkas,H., Anderson,J., Bernstein,J.A., Bouillet,L., Busse,P., Manning,M., Magerl,M., Gompels,M., Huissoon,A.P., Longhurst,H., Lumry,W., Ritchie,B., Shapiro,R., Soteres,D., Banerji,A., Cancian,M., Johnston,D.T., Craig,T.J., Launay,D., Li,H.H., Liebhaber,M., Nickel,T., Offenberger,J., Rae,W., Schrijvers,R., Triggiani,M., Wedner,H.J., Dobo,S., Cornpropst,M., Clemons,D., Fang,L., Collis,P., Sheridan,W.P. and Maurer,M. Evaluation of avoralstat, an oral kallikrein inhibitor, in a phase 3 hereditary angioedema prophylaxis trial: the OPUS-2 study Allergy (2018) 73, 1871-1880. PubMed Europe PubMed DOI I
Teufel,D.P., Bennett,G., Harrison,H., van Rietschoten,K., Pavan,S., Stace,C., Le Floch,F., Van Bergen,T., Vermassen,E., Barbeaux,P., Hu,T.T., Feyen,J.H.M. and Vanhove,M. Stable and long-lasting, novel bicyclic peptide plasma kallikrein inhibitors for the treatment of diabetic macular edema J Med Chem (2018) 61, 2823-2836. PubMed Europe PubMed DOI I
Xu,M., Chen,Y., Xu,P., Andreasen,P.A., Jiang,L., Li,J. and Huang,M. Crystal structure of plasma kallikrein reveals the unusual flexibility of the S1 pocket triggered by Glu217 FEBS Lett (2018) 592, 2658-2667. PubMed Europe PubMed DOI S

2017

Abdel-Magid,A.F. Plasma kallikrein inhibitors for the treatment of retinal vascular permeability associated with diabetic retinopathy and diabetic macular edema ACS Med Chem Lett (2017) 8, 776-777. PubMed Europe PubMed DOI PMC EPMC I
Ivanov,I., Matafonov,A., Sun,M.F., Cheng,Q., Dickeson,S.K., Verhamme,I.M., Emsley,J. and Gailani,D. Proteolytic properties of single-chain factor XII: a mechanism for triggering contact activation Blood (2017) 129, 1527-1537. PubMed Europe PubMed DOI
Li,Z., Partridge,J., Silva-Garcia,A., Rademacher,P., Betz,A., Xu,Q., Sham,H., Hu,Y., Shan,Y., Liu,B., Zhang,Y., Shi,H., Xu,Q., Ma,X. and Zhang,L. Structure-guided design of novel, potent, and selective macrocyclic plasma kallikrein inhibitors ACS Med Chem Lett (2017) 8, 185-190. PubMed Europe PubMed DOI PMC EPMC I
Simao,F., Ustunkaya,T., Clermont,A.C. and Feener,E.P. Plasma kallikrein mediates brain hemorrhage and edema caused by tissue plasminogen activator therapy in mice after stroke Blood (2017) 129, 2280-2290. PubMed Europe PubMed DOI
Steen Burrell,K.A., Layzer,J. and Sullenger,B.A. A kallikrein-targeting RNA aptamer inhibits the intrinsic pathway of coagulation and reduces bradykinin release J Thromb Haemost (2017) 15, 1807-1817. PubMed Europe PubMed DOI I
Xu,M.-M., Xu,P., Zhou,X.-L., Andreasen,P., Jiang,L.-G. and Huang,M.-D. Crystal structures of the serine protease domain of murine plasma kallikrein Jiegou Huaxue (2017) 36, 242-249. DOI S

2016

Clermont,A., Murugesan,N., Zhou,Q., Kita,T., Robson,P.A., Rushbrooke,L.J., Evans,D.M., Aiello,L.P. and Feener,E.P. Plasma kallikrein mediates vascular endothelial growth factor-induced retinal dysfunction and thickening Invest Ophthalmol Vis Sci (2016) 57, 2390-2399. PubMed Europe PubMed DOI PMC EPMC I
Cornpropst,M., Collis,P., Collier,J., Babu,Y.S., Wilson,R., Zhang,J., Fang,L., Zong,J. and Sheridan,W.P. Safety, pharmacokinetics, and pharmacodynamics of avoralstat, an oral plasma kallikrein inhibitor: phase 1 study Allergy (2016) 71, 1676-1683. PubMed Europe PubMed DOI I
Gittleman,H.R., Merkulova,A., Alhalabi,O., Stavrou,E.X., Veigl,M.L., Barnholtz-Sloan,J.S. and Schmaier,A.H. A cross-sectional study of KLKB1 and PRCP polymorphisms in patient samples with cardiovascular disease Front Med (Lausanne) (2016) 3, 17-17. PubMed Europe PubMed DOI PMC EPMC M
Gras,J. Anti-KLKB1 (plasma kallikrein) MAb treatment of hereditary angioedema Drugs Future (2016) 41, 281-284. DOI
Kokoye,Y., Ivanov,I., Cheng,Q., Matafonov,A., Dickeson,S.K., Mason,S., Sexton,D.J., Renne,T., McCrae,K., Feener,E.P. and Gailani,D. A comparison of the effects of factor XII deficiency and prekallikrein deficiency on thrombus formation Thromb Res (2016) 140, 118-124. PubMed Europe PubMed DOI M
Kolte,D. and Shariat-Madar,Z. Plasma kallikrein inhibitors in cardiovascular disease: an innovative therapeutic approach Cardiol Rev (2016) 24, 99-109. PubMed Europe PubMed DOI I

2015

Adamopoulos,P.G., Kontos,C.K., Papageorgiou,S.G., Pappa,V. and Scorilas,A. KLKB1 mRNA overexpression: a novel molecular biomarker for the diagnosis of chronic lymphocytic leukemia Clin Biochem (2015) 48, 849-854. PubMed Europe PubMed DOI
Renne,T. The vascular side of plasma kallikrein Blood (2015) 125, 589-590. PubMed Europe PubMed DOI K
Xu,P., Xu,M., Jiang,L., Yang,Q., Luo,Z., Dauter,Z., Huang,M. and Andreasen,P.A. Design of specific serine protease inhibitors based on a versatile peptide scaffold: conversion of a urokinase inhibitor to a plasma kallikrein inhibitor J Med Chem (2015) 58, 8868-8876. PubMed Europe PubMed DOI I

2014

Kenniston,J.A., Faucette,R.R., Martik,D., Comeau,S.R., Lindberg,A.P., Kopacz,K.J., Conley,G.P., Chen,J., Viswanathan,M., Kastrapeli,N., Cosic,J., Mason,S., DiLeo,M., Abendroth,J., Kuzmic,P., Ladner,R.C., Edwards,T.E., Tenhoor,C., Adelman,B.A., Nixon,A.E. and Sexton,D.J. Inhibition of plasma kallikrein by a highly specific active site blocking antibody J Biol Chem (2014) 289, 23596-23608. PubMed Europe PubMed DOI
Keum,J.S., Jaffa,M.A., Luttrell,L.M. and Jaffa,A.A. Novel mechanism of plasma prekallikrein (PK) activation by vascular smooth muscle cells: evidence of the presence of PK activator J Biol Regul Homeost Agents (2014) 28, 587-603. PubMed Europe PubMed
Schmaier,A.H. Physiologic activities of the contact activation system Thromb Res (2014) 133 Suppl 1, S41-S44. PubMed Europe PubMed DOI PMC EPMC K
Wang,J., Matafonov,A., Madkhali,H., Mahdi,F., Watson,D., Schmaier,A.H., Gailani,D. and Shariat-Madar,Z. Prolylcarboxypeptidase independently activates plasma prekallikrein (Fletcher factor) Curr Mol Med (2014) 14, 1173-1185. PubMed Europe PubMed

2013

Bjorkqvist,J., Jamsa,A. and Renne,T. Plasma kallikrein: the bradykinin-producing enzyme Thromb Haemost (2013) 110, 399-407. PubMed Europe PubMed DOI V
Koumandou,V.L. and Scorilas,A. Evolution of the plasma and tissue kallikreins, and their alternative splicing isoforms PLoS ONE (2013) 8, e68074-e68074. PubMed Europe PubMed DOI PMC EPMC
Wong,M.K. and Takei,Y. Lack of plasma kallikrein-kinin system cascade in teleosts PLoS ONE (2013) 8, e81057-e81057. PubMed Europe PubMed DOI PMC EPMC

2012

Baeriswyl,V., Rapley,H., Pollaro,L., Stace,C., Teufel,D., Walker,E., Chen,S., Winter,G., Tite,J. and Heinis,C. Bicyclic peptides with optimized ring size inhibit human plasma kallikrein and its orthologues while sparing paralogous proteases ChemMedChem (2012) 7, 1173-1176. PubMed Europe PubMed DOI I
Bird,J.E., Smith,P.L., Wang,X., Schumacher,W.A., Barbera,F., Revelli,J.P. and Seiffert,D. Effects of plasma kallikrein deficiency on haemostasis and thrombosis in mice: murine ortholog of the Fletcher trait Thromb Haemost (2012) 107, 1141-1150. PubMed Europe PubMed DOI K
Renne,T. and Gruber,A. Plasma kallikrein: novel functions for an old protease Thromb Haemost (2012) 107, 1012-1013. PubMed Europe PubMed DOI
Schmaier,A.H. Prekallikrein and plasma kallikrein [ISSN:978-0-12-407742-3] (2012) 3, 2885-2892. DOI

2011

Kolte,D., Bryant,J., Holsworth,D., Wang,J., Akbari,P., Gibson,G. and Shariat-Madar,Z. Biochemical characterization of a novel high-affinity and specific plasma kallikrein inhibitor Br J Pharmacol (2011) 162, 1639-1649. PubMed Europe PubMed DOI I
Revenko,A.S., Gao,D., Crosby,J.R., Bhattacharjee,G., Zhao,C., May,C., Gailani,D., Monia,B.P. and Macleod,A.R. Selective depletion of plasma prekallikrein or coagulation factor XII inhibits thrombosis in mice without increased risk of bleeding Blood (2011) 118, 5302-5311. PubMed Europe PubMed DOI K

2010

Stoop,A.A., Joshi,R.V., Eggers,C.T. and Craik,C.S. Analysis of an engineered plasma kallikrein inhibitor and its effect on contact activation Biol Chem (2010) 391, 425-433. PubMed Europe PubMed DOI

2009

Abid,K., Rochat,B., Lassahn,P.G., Stocklin,R., Michalet,S., Brakch,N., Aubert,J.F., Vatansever,B., Tella,P., De Meester,I. and Grouzmann,E. Kinetic study of neuropeptide Y (NPY) proteolysis in blood and identification of NPY3-35: a new peptide generated by plasma kallikrein J Biol Chem (2009) 284, 24715-24724. PubMed Europe PubMed DOI PMC EPMC P
Huang,W.Y., Wan,X. and Zhang,S. A novel chromogenic peptide for prekallikrein/kallikrein determination Clin Lab (2009) 55, 106-113. PubMed Europe PubMed A

2008

Lima,A.R., Alves,F.M., Angelo,P.F., Andrade,D., Blaber,S.I., Blaber,M., Juliano,L. and Juliano,M.A. S(1)' and S(2)' subsite specificities of human plasma kallikrein and tissue kallikrein 1 for the hydrolysis of peptides derived from the bradykinin domain of human kininogen Biol Chem (2008) 389, 1487-1494. PubMed Europe PubMed DOI P
Saito,A. Plasma kallikrein is activated on dermatan sulfate and cleaves factor H Biochem Biophys Res Commun (2008) 370, 646-650. PubMed Europe PubMed DOI
Schmaier,A.H. Assembly, activation, and physiologic influence of the plasma kallikrein/kinin system Int Immunopharmacol (2008) 8, 161-165. PubMed Europe PubMed DOI PMC EPMC V
Stief,T.W. Kallikrein activates prothrombin Clin Appl Thromb Hemost (2008) 14, 97-98. PubMed Europe PubMed DOI

2007

Colman,R. Kallikrein-kinin system (2007) 9780521853767, 444-450. DOI V
Hooley,E., McEwan,P.A. and Emsley,J. Molecular modeling of the prekallikrein structure provides insights into high-molecular-weight kininogen binding and zymogen activation J Thromb Haemost (2007) 5, 2461-2466. PubMed Europe PubMed DOI
Sainz,I.M., Pixley,R.A. and Colman,R.W. Fifty years of research on the plasma kallikrein-kinin system: from protein structure and function to cell biology and in-vivo pathophysiology Thromb Haemost (2007) 98, 77-83. PubMed Europe PubMed DOI V
Schmaier,A.H. and McCrae,K.R. The plasma kallikrein-kinin system: its evolution from contact activation J Thromb Haemost (2007) 5, 2323-2329. PubMed Europe PubMed DOI V
Schneider,L., Lumry,W., Vegh,A., Williams,A.H. and Schmalbach,T. Critical role of kallikrein in hereditary angioedema pathogenesis: a clinical trial of ecallantide, a novel kallikrein inhibitor J Allergy Clin Immunol (2007) 120, 416-422. PubMed Europe PubMed DOI

2006

[YEAR:4-11-2006]Biyashev,D., Tan,F., Chen,Z., Zhang,K., Deddish,P.A., Erdos,E.G. and Hecquet,C. Kallikrein activates bradykinin B2 receptors in absence of kininogen Am J Physiol Heart Circ Physiol (4-11-2006) 290, H1244-H1250. PubMed Europe PubMed DOI PMC EPMC
Levy,J.H. and O'Donnell,P.S. The therapeutic potential of a kallikrein inhibitor for treating hereditary angioedema Expert Opin Investig Drugs (2006) 15, 1077-1090. PubMed Europe PubMed DOI T
[YEAR:16-5-2006]Storini,C., Bergamaschini,L., Gesuete,R., Rossi,E., Maiocchi,D. and De Simoni,M.G. Selective inhibition of plasma kallikrein protects brain from reperfusion injury J Pharmacol Exp Ther (16-5-2006) 318, 849-854. PubMed Europe PubMed DOI
[YEAR:11-1-2006]Young,W.B., Rai,R., Shrader,W.D., Burgess-Henry,J., Hu,H., Elrod,K.C., Sprengeler,P.A., Katz,B.A., Sukbuntherng,J. and Mordenti,J. Small molecule inhibitors of plasma kallikrein Bioorg Med Chem Lett (11-1-2006) 16, 2034-2036. PubMed Europe PubMed DOI I
Zhang,J., Krishnan,R., Arnold,C.S., Mattsson,E., Kilpatrick,J.M., Bantia,S., Dehghani,A., Boudreaux,B., Gupta,S.N., Kotian,P.L., Chand,P. and Babu,Y.S. Discovery of highly potent small molecule kallikrein inhibitors Med Chem (2006) 2, 545-553. PubMed Europe PubMed I

2005

Moreau,M.E., Garbacki,N., Molinaro,G., Brown,N.J., Marceau,F. and Adam,A. The kallikrein-kinin system: current and future pharmacological targets J Pharmacol Sci (2005) 99, 6-38. PubMed Europe PubMed DOI V
Neth,P., Arnhold,M., Sidarovich,V., Bhoola,K.D. and Fink,E. Expression of the plasma prekallikrein gene: utilization of multiple transcription start sites and alternative promoter regions Biol Chem (2005) 386, 101-109. PubMed Europe PubMed DOI
Shariat-Madar,Z., Rahimy,E., Mahdi,F. and Schmaier,A.H. Overexpression of prolylcarboxypeptidase enhances plasma prekallikrein activation on Chinese hamster ovary cells Am J Physiol Heart Circ Physiol (2005) 289, H2697-H2703. PubMed Europe PubMed DOI
[YEAR:30-9-2005]Tang,J., Yu,C.L., Williams,S.R., Springman,E., Jeffery,D., Sprengeler,P.A., Estevez,A., Sampang,J., Shrader,W., Spencer,J., Young,W., McGrath,M. and Katz,B.A. Expression, crystallization, and three-dimensional structure of the catalytic domain of human plasma kallikrein J Biol Chem (30-9-2005) 280, 41077-41089. PubMed Europe PubMed DOI E S

2004

Colman,R.W. Plasma prekallikrein and kallikrein [ISSN:0-12-079610-4] (2004) 2, 1644-1651. V
[YEAR:2-3-2004]Shariat-Madar,Z., Mahdi,F. and Schmaier,A.H. Recombinant prolylcarboxypeptidase activates plasma prekallikrein Blood (2-3-2004) 103, 4554-4561. PubMed Europe PubMed DOI I
Tanaka,K.A., Szlam,F., Katori,N., Vega,J.D. and Levy,J.H. Evaluation of a novel kallikrein inhibitor on hemostatic activation in vitro Thromb Res (2004) 113, 333-339. PubMed Europe PubMed DOI
Wynne Jones,D., Russell,G., Allford,S.L., Burdon,K., Hawkins,G.A., Bowden,D.W., Minaee,S. and Mumford,A.D. Severe prekallikrein deficiency associated with homozygosity for an Arg94Stop nonsense mutation Br J Haematol (2004) 127, 220-223. PubMed Europe PubMed DOI

2003

Jaffa,A.A., Durazo-Arvizu,R., Zheng,D., Lackland,D.T., Srikanth,S., Garvey,W.T. and Schmaier,A.H. Plasma prekallikrein: a risk marker for hypertension and nephropathy in type 1 diabetes Diabetes (2003) 52, 1215-1221. PubMed Europe PubMed DOI
Lombardi,A.M., Sartori,M.T., Cabrio,L., Fadin,M., Zanon,E. and Girolami,A. Severe prekallikrein (Fletcher factor) deficiency due to a compound heterozygosis (383Trp stop codon and Cys529Tyr) Thromb Haemost (2003) 90, 1040-1045. PubMed Europe PubMed DOI M
Nunes,V.A., Gozzo,A.J., Sampaio,M.U., Juliano,M.A., Sampaio,C.A. and Araujo,M.S. Mapping of human plasma kallikrein active site by design of peptides based on modifications of a Kazal-type inhibitor reactive site J Protein Chem (2003) 22, 533-541. PubMed Europe PubMed DOI
Stoop,A.A. and Craik,C.S. Engineering of a macromolecular scaffold to develop specific protease inhibitors Nat Biotechnol (2003) 21, 1063-1068. PubMed Europe PubMed DOI

2002

[YEAR:22-1-2002]Joseph,K., Tholanikunnel,B.G. and Kaplan,A.P. Heat shock protein 90 catalyzes activation of the prekallikrein-kininogen complex in the absence of factor XII Proc Natl Acad Sci U S A (22-1-2002) 99, 896-900. PubMed Europe PubMed DOI PMC EPMC
[YEAR:6-12-2002]Peek,M., Moran,P., Mendoza,N., Wickramasinghe,D. and Kirchhofer,D. Unusual proteolytic activation of pro-hepatocyte growth factor by plasma kallikrein and coagulation factor XIa J Biol Chem (6-12-2002) 277, 47804-47809. PubMed Europe PubMed DOI
Renne,T., Sugiyama,A., Gailani,D., Jahnen-Dechent,W., Walter,U. and Muller-Esterl,W. Fine mapping of the H-kininogen binding site in plasma prekallikrein apple domain 2 Int Immunopharmacol (2002) 2, 1867-1873. PubMed Europe PubMed DOI
[YEAR:17-5-2002]Shariat-Madar,Z., Mahdi,F. and Schmaier,A.H. Identification and characterization of prolylcarboxypeptidase as an endothelial cell prekallikrein activator J Biol Chem (17-5-2002) 277, 17962-17969. PubMed Europe PubMed DOI
Shariat-Madar,Z., Mahdi,F. and Schmaier,A.H. Assembly and activation of the plasma kallikrein/kinin system: a new interpretation Int Immunopharmacol (2002) 2, 1841-1849. PubMed Europe PubMed DOI

2001

[YEAR:1-5-2001]Melo,R.L., Barbosa Pozzo,R.C., Pimenta,D.C., Perissutti,E., Caliendo,G., Santagada,V., Juliano,L. and Juliano,M.A. Human tissue kallikrein S1 subsite recognition of non-natural basic amino acids Biochemistry (1-5-2001) 40, 5226-5232. PubMed Europe PubMed
[YEAR:1-6-2001]Melo,R.L., Alves,L.C., Del Nery,E., Juliano,L. and Juliano,M.A. Synthesis and hydrolysis by cysteine and serine proteases of short internally quenched fluorogenic peptides Anal Biochem (1-6-2001) 293, 71-77. PubMed Europe PubMed DOI
Neth,P., Arnhold,M., Nitschko,H. and Fink,E. The mRNAs of prekallikrein, factors XI and XII, and kininogen, components of the contact phase cascade are differentially expressed in multiple non-hepatic human tissues Thromb Haemost (2001) 85, 1043-1047. PubMed Europe PubMed
Tada,M., Tsuda,Y., Wanaka,K., Hijikata-Okunomiya,A., Horie,N., Okamoto,U., Okamoto,S. and Okada,Y. Isolation of plasma kallikrein by high efficiency affinity chromatography and its characterization Biol Pharm Bull (2001) 24, 520-524. PubMed Europe PubMed DOI I

2000

Okada,Y., Tsuda,Y., Tada,M., Wanaka,K., Okamoto,U., Hijikata-Okunomiya,A. and Okamoto,S. Development of potent and selective plasmin and plasma kallikrein inhibitors and studies on the structure-activity relationship Chem Pharm Bull (Tokyo) (2000) 48, 1964-1972. PubMed Europe PubMed I
[YEAR:15-10-2000]Yu,H., Anderson,P.J., Freedman,B.I., Rich,S.S. and Bowden,D.W. Genomic structure of the human plasma prekallikrein gene, identification of allelic variants, and analysis in end-stage renal disease Genomics (15-10-2000) 69, 225-234. PubMed Europe PubMed DOI M

1999

Fukumizu,A., Tsuda,Y., Wanaka,K., Tada,M., Okamoto,S., Hijikata-Okunomiya,A. and Okada,Y. Amino acids and peptides. LIII. Synthesis and biological activities of some pseudo-peptide analogs of PKSI-527, a plasma kallikrein selective inhibitor: The importance of the peptide backbone Chem Pharm Bull (Tokyo) (1999) 47, 1141-1144. PubMed Europe PubMed I
Okada,Y., Tsuda,Y., Tada,M., Wanaka,K., Hijikata-Okunomiya,A., Okamoto,U. and Okamoto,S. Development of plasma kallikrein selective inhibitors Biopolymers (1999) 51, 41-50. PubMed Europe PubMed DOI I
[YEAR:3-9-1999]Renne,T., Dedio,J., Meijers,J.C., Chung,D. and Muller-Esterl,W. Mapping of the discontinuous H-kininogen binding site of plasma prekallikrein. Evidence for a critical role of apple domain-2 J Biol Chem (3-9-1999) 274, 25777-25784. PubMed Europe PubMed DOI
Shibuya,Y., Semba,U., Nishino,N., Khan,M.M., Tanase,S., Okabe,H. and Yamamoto,T. Primary structure of guinea pig plasma prekallikrein Immunopharmacology (1999) 45, 127-134. PubMed Europe PubMed DOI

1998

[YEAR:1-1-1998]Kohyama,K., Ohnishi,J., Murata,M. and Takahashi,T. Presence of follipsin complexed with alpha2-macroglobulin in porcine ovarian follicular fluid J Exp Zool (1-1-1998) 280, 57-64. PubMed Europe PubMed DOI
[YEAR:1-12-1998]Presnell,S.R., Patil,G.S., Mura,C., Jude,K.M., Conley,J.M., Bertrand,J.A., Kam,C.M., Powers,J.C. and Williams,L.D. Oxyanion-mediated inhibition of serine proteases Biochemistry (1-12-1998) 37, 17068-17081. PubMed Europe PubMed DOI S I
Rojkjaer,R., Hasan,A.A., Motta,G., Schousboe,I. and Schmaier,A.H. Factor XII does not initiate prekallikrein activation on endothelial cells Thromb Haemost (1998) 80, 74-81. PubMed Europe PubMed
Stadnicki,A., Sartor,R.B., Janardham,R., Majluf-Cruz,A., Kettner,C.A., Adam,A.A. and Colman,R.W. Specific inhibition of plasma kallikrein modulates chronic granulomatous intestinal and systemic inflammation in genetically susceptible rats FASEB J (1998) 12, 325-333. PubMed Europe PubMed
Tada,M., Wanaka,K., Okamoto,S., Okamoto,U., Nakaya,Y., Horie,N., Hijikata-Okunomiya,A., Tsuda,Y. and Okada,Y. Purification method for human plasma kallikrein by a new affinity chromatography Biol Pharm Bull (1998) 21, 105-108. PubMed Europe PubMed I
Tsuda,Y., Wanaka,K., Tada,M., Okamoto,S., Hijikata-Okunomiya,A. and Okada,Y. Design of plasma kallikrein inhibitors: functional and structural requirements of plasma kallikrein inhibitors Chem Pharm Bull (Tokyo) (1998) 46, 452-457. PubMed Europe PubMed I
Yu,H., Bowden,D.W., Spray,B.J., Rich,S.S. and Freedman,B.I. Identification of human plasma kallikrein gene polymorphisms and evaluation of their role in end-stage renal disease Hypertension (1998) 31, 906-911. PubMed Europe PubMed M

1997

[YEAR:15-7-1997]Lin,Y., Harris,R.B., Yan,W., McCrae,K.R., Zhang,H. and Colman,R.W. High molecular weight kininogen peptides inhibit the formation of kallikrein on endothelial cell surfaces and subsequent urokinase-dependent plasmin formation Blood (15-7-1997) 90, 690-697. PubMed Europe PubMed

1996

Katsuura,Y., Okamoto,S., Ohno,N. and Wanaka,K. Effects of a highly selective synthetic inhibitor of plasma kallikrein on disseminated intravascular coagulation in rats Thromb Res (1996) 82, 361-368. PubMed Europe PubMed DOI I
Mashiko,H., Kato,K., Fujii,K. and Takahashi,H. Studies on factor XII in porcine plasma: Purification and its conversion to activated form by porcine plasma kallikrein Biochim Biophys Acta (1996) 1296, 198-206. PubMed Europe PubMed DOI
Yamamoto,T., Shibuya,Y. and Semba,U. Species differences in amino acid sequences of Hageman factor and prekallikrein at region around scissile bond in activation Immunopharmacology (1996) 32, 34-38. PubMed Europe PubMed DOI

1995

Ohnishi,J., Kihara,T., Hamabata,T., Takahashi,K. and Takahashi,T. Cleavage specificity of porcine follipsin J Biol Chem (1995) 270, 19391-19394. PubMed Europe PubMed DOI
Ulmer,J.S., Lindquist,R.N., Dennis,M.S. and Lazarus,R.A. Ecotin is a potent inhibitor of the contact system proteases factor XIIa and plasma kallikrein FEBS Lett (1995) 365, 159-163. PubMed Europe PubMed DOI
Wachtfogel,Y.T., Hack,C.E., Nuijens,J.H., Kettner,C., Reilly,T.M., Knabb,R.M., Bischoff,R., Tschesche,H., Wenzel,H. and Kucich,U. Selective kallikrein inhibitors alter human neutrophil elastase release during extracorporeal circulation Am J Physiol (1995) 268, H1352-H1357. PubMed Europe PubMed I

1994

Hamabata,T., Okimura,H., Yokoyama,N., Takahashi,T. and Takahashi,K. Purification, characterization, and localization of follipsin, a novel serine proteinase from the fluid of porcine ovarian follicles J Biol Chem (1994) 269, 17899-17904. PubMed Europe PubMed
Page,J.D., DeLa Cadena,R.A., Humphries,J.E. and Colman,R.W. An autoantibody to human plasma prekallikrein blocks activation of the contact system Br J Haematol (1994) 87, 81-86. PubMed Europe PubMed
Pu,X.P., Iwamoto,A., Nishimura,H. and Nagasawa,S. Purification and characterization of a novel substrate for plasma kallikrein (PK-120) in human plasma Biochim Biophys Acta (1994) 1208, 338-343. PubMed Europe PubMed DOI

1993

[YEAR:30-12-1993]Ciechanowicz,A., Bader,M., Wagner,J. and Ganten,D. Extra-hepatic transcription of plasma prekallikrein gene in human and rat tissues Biochem Biophys Res Commun (30-12-1993) 197, 1370-1376. PubMed Europe PubMed DOI
Teno,N., Wanaka,K., Okada,Y., Taguchi,H., Okamoto,U., Hijikata-Okunomiya,A. and Okamoto,S. Development of active center-directed plasmin and plasma kallikrein inhibitors and studies on the structure-inhibitory activity relationship Chem Pharm Bull (Tokyo) (1993) 41, 1079-1090. PubMed Europe PubMed I

1992

Imamura,T. and Kambara,T. The major plasma kallikrein inhibitor of guinea pig plasma Biochim Biophys Acta (1992) 1118, 261-266. PubMed Europe PubMed DOI
Okamoto,S., Wanaka,K., Hijikata-Okunomiya,A., Okada,Y. and Katsuura,Y. A finding of highly selective synthetic inhibitor of plasma kallikrein; its action to bradykinin generation, intrinsic coagulation and experimental DIC Agents Actions Suppl (1992) 38, 198-205. PubMed Europe PubMed I
Tanaka,H., Yamamoto,T., Shibuya,Y., Nishino,N., Tanase,S., Miyauchi,Y. and Kambara,T. Activation of human plasma prekallikrein by Pseudomonas aeruginosa elastase. II. Kinetic analysis and identification of scissile bond of prekallikrein in the activation Biochim Biophys Acta (1992) 1138, 243-250. PubMed Europe PubMed

1991

Beaubien,G., Rosinski-Chupin,I., Mattei,M.G., Mbikay,M., Chretien,M. and Seidah,N.G. Gene structure and chromosomal localization of plasma kallikrein Biochemistry (1991) 30, 1628-1635. PubMed Europe PubMed
Teno,N., Wanaka,K., Okada,Y., Tsuda,Y., Okamoto,U., Hijikata-Okunomiya,A., Naito,T. and Okamoto,S. Development of selective inhibitors against plasma kallikrein Chem Pharm Bull (Tokyo) (1991) 39, 2930-2936. PubMed Europe PubMed I

1990

Seidah,N.G., Sawyer,N., Hamelin,J., Mion,P., Beaubien,G., Brachpapa,L., Rochemont,J., Mbikay,M. and Chretien,M. Mouse plasma kallikrein: cDNA structure, enzyme characterization, and comparison of protein and mRNA levels among species DNA Cell Biol (1990) 9, 737-748. PubMed Europe PubMed

1989

Hauert,J., Nicoloso,G., Schleuning,W.D., Bachmann,F. and Schapira,M. Plasminogen activators in dextran sulfate-activated euglobulin fractions: a molecular analysis of factor XII- and prekallikrein-dependent fibrinolysis Blood (1989) 73, 994-999. PubMed Europe PubMed
Seidah,N.G., Ladenheim,R., Mbikay,M., Hamelin,J., Lutfalla,G., Rougeon,F., Lazure,C. and Chretien,M. The cDNA structure of rat plasma kallikrein DNA (1989) 8, 563-574. PubMed Europe PubMed
Tsuda,Y., Teno,N., Okada,Y., Wanaka,K., Bohgaki,M., Hijikata-Okunomiya,A., Okamoto,U., Naito,T. and Okamoto,S. Synthesis of tripeptide chloromethyl ketones and examination of their inhibitory effects on plasmin and plasma kallikrein Chem Pharm Bull (Tokyo) (1989) 37, 3108-3111. PubMed Europe PubMed I

1988

Metters,K.M., Rossier,J., Paquin,J., Chretien,M. and Seidah,N.G. Selective cleavage of proenkephalin-derived peptides (less than 23,300 daltons) by plasma kallikrein J Biol Chem (1988) 263, 12543-12553. PubMed Europe PubMed P
Silverberg,M. and Kaplan,A.P. Prekallikrein Methods Enzymol (1988) 163, 85-95. PubMed Europe PubMed V

1987

De La Cadena,R.A., Scott,C.F. and Colman,R.W. Evaluation of a microassay for human plasma prekallikrein J Lab Clin Med (1987) 109, 601-607. PubMed Europe PubMed
Tans,G., Rosing,J., Berrettini,M., Lammle,B. and Griffin,J.H. Autoactivation of human plasma prekallikrein J Biol Chem (1987) 262, 11308-11314. PubMed Europe PubMed
Veloso,D., Silver,L.D., Hahn,S. and Colman,R.W. A monoclonal anti-human plasma prekallikrein antibody that inhibits activation of prekallikrein by factor XIIa on a surface Blood (1987) 70, 1053-1062. PubMed Europe PubMed

1986

Bouma,B.N., Kerbiriou,D.M., Baker,J. and Griffin,J.H. Characterization of a variant prekallikrein, prekallikrein Long Beach, from a family with mixed cross-reacting material-positive and cross-reacting material-negative prekallikrein deficiency J Clin Invest (1986) 78, 170-176. PubMed Europe PubMed DOI PMC EPMC
Burger,D., Schleuning,W.D. and Schapira,M. Human plasma prekallikrein. Immunoaffinity purification and activation to alpha- and beta-kallikrein J Biol Chem (1986) 261, 324-327. PubMed Europe PubMed
[YEAR:6-5-1986]Chung,D.W., Fujikawa,K., McMullen,B.A. and Davie,E.W. Human plasma prekallikrein, a zymogen to a serine protease that contains four tandem repeats Biochemistry (6-5-1986) 25, 2410-2417. PubMed Europe PubMed
Cromlish,J.A., Seidah,N.G. and Chretien,M. A novel serine protease (IRCM-serine protease 1) from porcine neurointermediate and anterior pituitary lobes. Isolation, polypeptide chain structure, inhibitor sensitivity, and substrate specificity with fluorogenic peptide substrates J Biol Chem (1986) 261, 10850-10858. PubMed Europe PubMed
Cromlish,J.A., Seidah,N.G. and Chretien,M. Selective cleavage of human ACTH, alpha-lipotropin, and the N- terminal glycopeptide at pairs of basic residues by IRCM-serine protease 1 J Biol Chem (1986) 261, 10859-10870. PubMed Europe PubMed
Schapira,M., Ramus,M.A., Jallat,S., Carvallo,D. and Courtney,M. Recombinant alpha1-antitrypsin Pittsburgh (Met 358->Arg) is a potent inhibitor of plasma kallikrein and activated factor XII fragment J Clin Invest (1986) 77, 635-637. PubMed Europe PubMed DOI PMC EPMC M
Tait,J.F. and Fujikawa,K. Identification of the binding site for plasma prekallikrein in human high molecular weight kininogen. A region from residues 185 to 224 of the kininogen light chain retains full binding activity J Biol Chem (1986) 261, 15396-15401. PubMed Europe PubMed

1982

Fisher,C.A., Schmaier,A.H., Addonizio,V.P. and Colman,R.W. Assay of prekallikrein in human plasma: comparison of amidolytic, esterolytic, coagulation, and immunochemical assays Blood (1982) 59, 963-970. PubMed Europe PubMed A
[YEAR:1-2-1982]Gallimore,M.J. and Friberger,P. Simple chromogenic peptide substrate assays for determining prekallikrein, kallikrein inhibition and kallikrein "like" activity in human plasma Thromb Res (1-2-1982) 25, 293-298. PubMed Europe PubMed

1981

Heimark,R.L. and Davie,E.W. Bovine and human plasma prekallikrein Methods Enzymol (1981) 80, 157-172. PubMed Europe PubMed DOI V
McRae,B.J., Kurachi,K., Heimark,R.L., Fujikawa,K., Davie,E.W. and Powers,J.C. Mapping the active sites of bovine thrombin, factor IXa, factor Xa, factor XIa, factor XIIa, plasma kallikrein, and trypsin with amino acid and peptide thioesters: development of new sensitive substrates Biochemistry (1981) 20, 7196-7206. PubMed Europe PubMed
Nagase,H. and Barrett,A.J. Human plasma kallikrein. A rapid purification method with high yield Biochem J (1981) 193, 187-192. PubMed Europe PubMed PMC EPMC
[YEAR:15-10-1981]Saito,H., Goodnough,L.T., Soria,J., Soria,C., Aznar,J. and Espana,F. Heterogeneity of human prekallikrein deficiency (Fletcher trait): evidence that five of 18 cases are positive for cross-reacting material N Engl J Med (15-10-1981) 305, 910-914. PubMed Europe PubMed DOI

1980

Jackson,C.M. and Nemerson,Y. Blood coagulation Annu Rev Biochem (1980) 49, 765-811. PubMed Europe PubMed DOI

1979

Davie,E.W., Fujikawa,K., Kurachi,K. and Kisiel,W. The role of serine proteases in the blood coagulation cascade Adv Enzymol Relat Areas Mol Biol (1979) 48, 277-318. PubMed Europe PubMed
Heimark,R.L. and Davie,E.W. Isolation and characterization of bovine plasma prekallikrein (Fletcher factor) Biochemistry (1979) 18, 5743-5750. PubMed Europe PubMed
Saito,H., Goldsmith,G.H., Moroi,M. and Aoki,N. Inhibitory spectrum of alpha2-plasmin inhibitor Proc Natl Acad Sci U S A (1979) 76, 2013-2017. PubMed Europe PubMed PMC EPMC
Soulier,J.P. and Gozin,D. Assay of Fletcher factor (plasma prekallikrein) using an artificial clotting reagent and a modified chromogenic assay Thromb Haemost (1979) 42, 538-547. PubMed Europe PubMed A
Yokosawa,N., Takahashi,N., Inagami,T. and Page,D.L. Isolation of completely inactive plasma prorenin and its activation by kallikreins. A possible new link between renin and kallikrein Biochim Biophys Acta (1979) 569, 211-219. PubMed Europe PubMed

1978

Gallimore,M.J., Fareid,E. and Stormorken,H. The purification of a human plasma kallikrein with weak plasminogen activator activity Thromb Res (1978) 12, 409-420. PubMed Europe PubMed DOI

1977

Morita,T., Kato,H., Iwanaga,S., Takada,K., Kimura,T. and Sakakibara,S. New fluorogenic substrates for alpha-thrombin, factor Xa, kallikreins, and urokinase J Biochem (1977) 82, 1495-1498. PubMed Europe PubMed A
[YEAR:13-10-1977]Tamura,Y., Hirado,M., Okamura,K., Minato,Y. and Fujii,S. Synthetic inhibitors of trypsin, plasmin, kallikrein, thrombin, C1r, and C1 esterase Biochim Biophys Acta (13-10-1977) 484, 417-422. PubMed Europe PubMed I

1976

Colman,R.W. and Bagdasarian,A. Human kallikrein and prekallikrein Methods Enzymol (1976) 45, 303-322. PubMed Europe PubMed DOI V
Lahiri,B., Bagdasarian,A., Mitchell,B., Talamo,R.C. and Colman,R.W. Antithrombin-heparin cofactor: an inhibitor of plasma kallikrein Arch Biochem Biophys (1976) 175, 737-747. PubMed Europe PubMed

1975

Saito,H. and Ratnoff,O.D. Alteration of factor VII activity by activated Fletcher factor (a plasma kallikrein): a potential link between the intrinsic and extrinsic blood-clotting systems J Lab Clin Med (1975) 85, 405-415. PubMed Europe PubMed

1974

Abildgaard,C.F. and Harrison,J. Fletcher factor deficiency: family study and detection Blood (1974) 43, 641-644. PubMed Europe PubMed M
Saito,H., Ratnoff,O.D. and Donaldson,V.H. Defective activation of clotting, fibrinolytic, and permeability-enhancing systems in human Fletcher trait plasma Circ Res (1974) 34, 641-651. PubMed Europe PubMed

1973

Cochrane,C.G., Revak,S.D. and Wuepper,W.G. Activation of Hageman factor in solid and fluid phases. A critical role of kallikrein J Exp Med (1973) 138, 1564-1583. PubMed Europe PubMed

1970

Hattersley,P.G. and Hayse,D. Fletcher factor deficiency: a report of three unrelated cases Br J Haematol (1970) 18, 411-416. PubMed Europe PubMed M

1969

[YEAR:29-4-1969]Colman,R.W. Activation of plasminogen by human plasma kallikrein Biochem Biophys Res Commun (29-4-1969) 35, 273-279. PubMed Europe PubMed
Colman,R.W., Mattler,L. and Sherry,S. Studies on the prekallikrein (kallikreinogen)-kallikrein enzyme system of human plasma. 2. Evidence relating the kaolin-activated arginine esterase to plasma kallikrein J Clin Invest (1969) 48, 23-32. PubMed Europe PubMed DOI PMC EPMC I
Ratnoff,O.D., Pensky,J., Ogston,D. and Naff,G.B. The inhibition of plasmin, plasma kallikrein, plasma permeability factor, and the C'1r subcomponent of the first component of complement by serum C'1 esterase inhibitor J Exp Med (1969) 129, 315-331. PubMed Europe PubMed PMC EPMC

1968

Nagasawa,S., Takahashi,H., Koida,M., Suzuki,T. and Schoenmakers,J.G. Partial purification of bovine plasma kallikreinogen, its activation by the Hageman factor Biochem Biophys Res Commun (1968) 32, 644-649. PubMed Europe PubMed

1960

Webster,M.E. and Pierce,J.V. Studies on plasma kallikrein and its relationship to plasmin J Pharmacol Exp Ther (1960) 130, 484-491. PubMed Europe PubMed